ProCE Banner Activity

First-line Therapy in NSCLC: What You Need to Know From AACR 2018

Clinical Thought
The optimal treatment of newly diagnosed patients with advanced NSCLC is changing. Here is how new findings reported at AACR 2018 are affecting my clinical practice.

Released: June 01, 2018

Share

Faculty

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Celgene TEXT Only

Genentech TEXT Only

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Takeda Oncology

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Mersana Therapeutics, and Novartis and funds for research support paid to his institution from Merck and OncoMed.